• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Actuated Medical Launches Participating Preferred Series A Round, Led by Keiretsu Forum Mid-Atlantic, South-East, & Texas

By: PRLog
May 08, 2025 at 13:37 PM EDT
BELLEFONTE, Pa. - May 8, 2025 - PRLog -- Actuated Medical, a pioneering company dedicated to developing innovative medical device solutions, is thrilled to announce the successful launch of the $1.5M First Tranche of their $10M Series A with Participating Preferred Shares. This significant financing milestone comes after successful due diligence and the execution of a term sheet with lead investor Keiretsu Forum Mid-Atlantic, South-East, & Texas (MST).

This funding will allow Actuated Medical to execute on commercialization milestones generated through discussions with Strategic Partners with interest in Actuated Medical technologies. The financing goal is to commercialize two FDA cleared medical devices and, in parallel, grow their clinical neural device portfolio.

Neural implants have the potential to treat neural diseases like Parkinson's and Epilepsy by using small electrical fields to mitigate the disruptive signals causing symptoms.  Actuated Medical's neural device team is working to solve two major challenges with neural implants – how to insert them precisely and gently to target, and how to keep the body from walling them off with scar tissue.  The goal is to revolutionize the approach to neural device design, placement, and treatment approaches.

"We are excited to partner with Keiretsu Forum-MST, whose expertise and network will be invaluable as we move forward," said Maureen L. Mulvihill, CEO of Actuated Medical. "This investment tranche marks a pivotal moment in our journey, allowing us to bring our innovative solutions to market more quickly and effectively."

Keiretsu Forum-MST is recognized for its commitment to supporting innovative companies through strategic investments and resources. Their involvement will not only provide financial backing but also strategic guidance as Actuated Medical seeks to enhance its product offerings and expand its reach in the healthcare sector.

"Actuated Medical exemplifies the kind of company we look for at Keiretsu Forum—innovative, capital-efficient, and led by a proven entrepreneur," said Howard Lubert, Regional President Keiretsu Forum-MST. "Dr. Maureen L. Mulvihill's ability to advance multiple technologies using over $48 million in non-dilutive funding is nothing short of extraordinary. This Series A round is a strategic step toward commercializing breakthrough solutions that can significantly improve patient care."

Actuated Medical remains committed to its mission of improving patient outcomes and accessibility to advanced medical technologies. The support from the Keiretsu Forum demonstrates confidence in their vision, and the possibilities ahead.

About Actuated Medical, Inc.

Actuated Medical is a medical technology innovator that is pioneering motion-based solutions to address critical, unmet clinical needs in gastroenterology and neurology. With an unwavering focus on innovation, safety, and superior quality, the Actuated team is committed to delivering transformative products that empower healthcare professionals to achieve greater precision, enhance efficiency, and drive better patient outcomes while reducing healthcare costs. The company's technologies are backed by a strategic path to commercialization with multiple exit opportunities, supported by invaluable feedback from industry leaders. Actuated holds 43 issued U.S. and international patents, 8 FDA 510(k) clearances, 5 Investigational Device Exemptions (IDEs), 33 pre-submissions, and has completed or is conducting 8 clinical studies. Actuated has been honored with two Small Business Administration (SBA) Tibbetts Awards for SBIR commercialization excellence (2014 & 2020). Actuated operates out of a state-of-the-art 20,000 sq. ft. facility in central Pennsylvania, and is certified ISO 13485, reflecting its steadfast commitment to quality and innovation. actuatedmedical.com

About Keiretsu Forum:

Keiretsu Forum is the world's largest private equity angel investment network, with over 2,000 accredited investors across 34 North American and 23 international chapters. The forum has invested over $1 billion in early-stage companies in the past 23 years, covering diverse sectors such as technology, life sciences, fintech, and sustainable technologies.

###

For media inquiries, please contact Maureen L. Mulvihill, Ph.D. by phone at 814-355-0003 or email at info@actuatedmedical.com.

Additional information can be found by visiting:
ActuatedMedical.com
ActuatedNeuroscience.com
TubeClear.com
GripTract.com

Photos: (Click photo to enlarge)

Actuated Medical Inc. Logo


Source: Actuated Medical, Inc.

Read Full Story - Actuated Medical Launches Participating Preferred Series A Round, Led by Keiretsu Forum Mid-Atlantic, South-East, & Texas | More news from this source

Press release distribution by PRLog

More News

View More
Spire Global: Tiny Satellites, Big Buy Ratings and Upside
Today 12:10 EDT
Via MarketBeat
Tickers SPIR
Energy Fuels: Is This America's Most Strategic Stock?
Today 9:18 EDT
Via MarketBeat
Topics Economy Supply Chain
Tickers UUUU
Silver and Gold Break Out—3 Names to Ride The Wave
Today 8:07 EDT
Via MarketBeat
Topics ETFs
Tickers GLD HL IAU SPY
MarketBeat Week in Review – 09/01 - 09/05
Today 7:00 EDT
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers AFRM AMBA AMZN AVGO DELL GOOGL
Why DocuSign Could Be a SaaS Value Play After Q2 Earnings
September 05, 2025
Via MarketBeat
Topics Earnings
Tickers DOCU
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap